Core Viewpoint - Daiwa Capital Markets maintains a target price of HKD 7.8 and a "Buy" rating for Alibaba Health (00241), highlighting that the company's revenue and adjusted net profit for the first half of the fiscal year 2026 increased by 17% and 38.7% year-on-year, respectively, exceeding both the firm's and market expectations [1] Financial Performance - Alibaba Health's revenue and adjusted net profit for the first half of fiscal year 2026 grew by 17% and 38.7% year-on-year, surpassing expectations [1] - The company reiterated its fiscal year 2026 targets for revenue and adjusted net profit growth rates of 10-15% and 20-30%, respectively [1] Growth Projections - The firm anticipates that Alibaba Health's revenue and adjusted net profit will achieve compound annual growth rates (CAGR) of 13% and 24%, respectively, from fiscal years 2026 to 2028, driven by ongoing growth in innovative drugs and health products, deeper synergies with the Alibaba ecosystem, and the expanding application of AI [1]